|
Effect of prior treatment (tx) on the clinical activity of imetelstat (IME) in transfusion-dependent (TD) patients (pts) with erythropoiesis-stimulating agent (ESA), relapsed or refractory (R/R)/ineligible lower-risk myelodysplastic syndromes (LR-MDS). |
| |
|
Stock and Other Ownership Interests - Abbvie |
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; DSI; Genentech; Geron; Janssen; Jazz Pharmaceuticals; Pharmaessentia; Rigel; Servio; SOBI; Sumitomo Pharma Oncology |
Speakers' Bureau - Jazz Pharmaceuticals; Pharmaessentia; Rigel; SERVIER; SOBI |
Research Funding - Bristol-Myers Squibb/Celgene (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Jazz Pharmaceuticals; Pharmaessentia |
| |
|
Honoraria - Celgene/Bristol-Myers Squibb; Novartis |
Consulting or Advisory Role - Abbvie; Ascentage Pharma; Celgene/Bristol-Myers Squibb; Curis; Geron; Gilead Sciences; GlaxoSmithKline; Keros Therapeutics; Novartis; Otsuka; SERVIER; Syros Pharmaceuticals |
Research Funding - Celgene (Inst) |
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Jazz Pharmaceuticals |
| |
|
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis |
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis |
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst) |
| |
|
Consulting or Advisory Role - Agios; AstraZeneca; Bristol-Myers Squibb/Celgene; Kurome Therapeutics; Syros Pharmaceuticals |
Research Funding - Bristol-Myers Squibb (Inst); Rigel (Inst); Takeda (Inst) |
| |
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb |
| |
|
Leadership - GRAIL; TFC Therapeutics |
Stock and Other Ownership Interests - TFC Therapeutics |
Honoraria - Epizyme; Taiho Oncology |
Consulting or Advisory Role - Genzyme; Janssen; Takeda; TFC Therapeutics |
Research Funding - GRAIL; Immuneel Therapeutics; Rarecells; Regeneron |
Patents, Royalties, Other Intellectual Property - Alercell; TFC Therapeutics |
Travel, Accommodations, Expenses - GRAIL; Rarecells |
| |
|
Employment - CanaLean , a start-up, developing an anti-lipid agent |
Stock and Other Ownership Interests - CannaLean |
Consulting or Advisory Role - Dr. Reddy's Laboratories; Rafa Pharmaceutical |
Speakers' Bureau - Novartis |
Research Funding - Abbvie (Inst); BMS (Inst); Novartis (Inst) |
| |
|
Honoraria - Abbvie; Astellas Pharma; BMSi; Novartis |
Travel, Accommodations, Expenses - Abbvie; Amgen |
| |
|
Honoraria - BMSi; Taiho Oncology |
Consulting or Advisory Role - BMSi; Keros Therapeutics; MDS Foundation |
Research Funding - BMSi (Inst); Taiho Pharmaceutical (Inst) |
(OPTIONAL) Uncompensated Relationships - BMSi |
| |
|
Honoraria - Celgene; Jazz Pharmaceuticals; Novartis |
Consulting or Advisory Role - Celgene |
Research Funding - Celgene (Inst); Novartis (Inst); Novartis (Inst) |
| |
|
Honoraria - Blueprint Medicines; Bristol Myers Squibb; GERON; Kura Oncology; MorphoSys; Novartis; OncLive/MJH Life Sciences; Rigel; Sierra Oncology; SOBI; Stemline Therapeutics; Taiho Oncology |
Consulting or Advisory Role - Geron |
Travel, Accommodations, Expenses - Blueprint Medicines; MorphoSys |
| |
|
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; Keros Therapeutics; Novartis |
Consulting or Advisory Role - AGIOS; Ascentage Pharma; Bristol-Myers Squibb/Celgene; Curis; GlaxoSmithKline; HEMAVAN; Keros Therapeutics; Otsuka; Syros Pharmaceuticals |
Travel, Accommodations, Expenses - Gilead Sciences; Novartis |
| |
|
Consulting or Advisory Role - Amgen; BMS; Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; NOVARTIS; Pfizer; Sanofi; SOBI; Takeda |
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; BMS; Celgene; Gebro Pharma; GlaxoSmithKline; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; Sanofi/Aventis; SOBI |
Travel, Accommodations, Expenses - Amgen; Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Geron |
| |
|
|
Stock and Other Ownership Interests - Geron |
| |
|
|
Stock and Other Ownership Interests - Geron |
| |
|
|
Stock and Other Ownership Interests - Geron |
| |
|
Stock and Other Ownership Interests - Empath Biosciencies; Karyopharm Therapeutics; Ryvu Therapeutics |
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; Geron; Karyopharm Therapeutics; Novartis; Ryvu Therapeutics; Sierra Oncology |
Research Funding - ALX Oncology; Astex Pharmaceuticals; Incyte; Takeda Israel |
Travel, Accommodations, Expenses - Astex Pharmaceuticals |
| |
|
No Relationships to Disclose |